Please assess the completion status of the following clinical trial:

Trial Title: S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Previously untreated multiple myeloma~  * Stage I, II, or III disease by the International Staging System~* Measurable M-protein as defined by 1 of the following:~  * Serum M-protein at least 1.0 g/dL by serum protein electrophoresis or immunoelectrophoresis~ * Urinary M-protein excretion at least 200 mg/24 hours~* No nonsecretory multiple myeloma~* Not planning to undergo future autologous stem cell transplantation~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* Zubrod 0-3\* NOTE: \*Zubrod 3 allowed only if multiple myeloma is the central cause of disability~Life expectancy~* Not specified~Hematopoietic~* Platelet count at least 80,000/mm\^3\*~* Absolute neutrophil count at least 1,000/mm\^3\*~* Hemoglobin at least 9 g/dL\* (epoetin alfa or transfusion allowed) NOTE: \*Unless due to greater than 50% marrow involvement by myeloma on biopsy~Hepatic~* AST/ALT no greater than 3 times upper limit of normal\* NOTE: \*Values outside of this range are allowed at the investigator's discretion~Renal~* Creatinine no greater than 2.5 mg/dL\* NOTE: \*Values outside of this range are allowed at the investigator's discretion~Cardiovascular~* No New York Heart Association class III or IV heart failure~* No myocardial infarction within the past 6 months~* No poorly controlled hypertension~Other~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception for 4 weeks before, during, and for 4 weeks after study treatment~  * Female patients must use 2 reliable forms of contraception simultaneously~ * Male patients must use effective barrier contraception~* No uncontrolled active infection requiring IV antibiotics~* No poorly controlled diabetes mellitus that would preclude ability to take oral glucocorticoids~* No other serious medical condition that would preclude study participation~* No psychiatric illness that would preclude study participation~* No other malignancy within the past 3 years except adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix~* Must be able to take aspirin by mouth at a dose of 325 mg per day or enoxaparin subcutaneously at a dose of 40 mg per day as a form of thrombotic prophylaxis, except if already on therapeutic anticoagulant medication~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior interferon or thalidomide~Chemotherapy~* No prior chemotherapy~Endocrine therapy~* Prior high-dose dexamethasone allowed provided duration of administration was no more than 4 days~Radiotherapy~* Prior localized radiotherapy allowed provided it was not to the sole site of evaluable disease~Surgery~* Not specified~Other~* No prior treatment for clinically significant ventricular cardiac arrhythmias~* Concurrent bisphosphonates allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: EXPERIMENTAL): Patients receive induction therapy comprising oral dexamethasone (DM) on days 1-4, 9-12, and 17-20 and oral lenalidomide on days 1-28. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive maintenance therapy comprising oral DM on days 1-4 and 15-18 and oral lenalidomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
- Arm II (Type: ACTIVE_COMPARATOR): Patients receive induction therapy comprising DM as in arm I induction and oral placebo on days 1-28. Treatment repeats as in arm I induction. Some patients may then receive maintenance therapy comprising oral DM as in arm I maintenance and oral placebo on days 1-21. Courses repeat as in arm I maintenance.

Based on this trial design, predict the completion outcome and termination type (if applicable).